Malignant mesothelioma is deadly and rare type of cancer that affects the mesothelium, a membrane that forms a thin lining of the body’s internal organs (pleurae, peritoneum, and pericardium). The mesothelium makes a special lubricating fluid that helps to protect the organs and allows organs to move against each other. Some major symptoms include shortness of breath, chest pain, and cough. It takes around 35 to 50 years for the symptoms to manifest. Malignant Mesothelioma, can occur at any age; however, it is common in adults aged 65 and above. It is more common in men as compared to women, the male to female ratio is 3:1. Malignant mesothelioma accounts for 1% of all cancers worldwide. People exposed to asbestos (industrial pollutant), are at a higher risk of developing malignant mesothelioma. The risk of mesothelioma is increased in polluted areas by 2 to 10 fold as compared to non-polluted areas. Additionally, people who are exposed to a high dose of radiation, zeolites (minerals chemically related to asbestos), and suffering from simian virus 40 infection are at a risk of developing malignant mesothelioma.
In terms of type, the malignant mesothelioma market can be segmented into malignant pleural mesothelioma (occurs in the lining of the lungs), malignant peritoneal mesothelioma (occurs in the lining of the abdomen), and malignant pericardial mesothelioma (occurs in the lining of the heart). The malignant pleural mesothelioma segment is anticipated to grow because it accounts 70% of all mesothelioma cases followed by malignant peritoneal mesothelioma which accounts 15-20% of all mesothelioma cases. In terms of treatment, the malignant mesothelioma market can be segmented into surgery, chemotherapy, and radiotherapy. Surgery includes pneumonectomy, debulking, and omentectomy and is preferred treatment for malignant mesothelioma. Patients who successfully underwent surgical resection have a high surveillance rate (significantly 5 years). Radiation helps to shrink the tumor size and is often used as an adjuvant therapy. Chemotherapy plays an important role in palliative care. A number of companies such as AstraZeneca are involved in research and development of therapeutics for malignant mesothelioma. Major pipeline molecules include durvalumab, tazemetostat, tremelimumab, nintedanib, ADI-PEG 20, and HSV 1716. Therapeutic pipeline is anticipated to witness considerable growth in the malignant mesothelioma market in the near future due to increase in incidence rate, rising air pollution, rising geriatric population, and increase healthcare expenditure. Additionally, the development of novel therapy and introduction to advance treatment options are likely to provide lucrative growth opportunities to the malignant mesothelioma market during the forecast period. However, long latent period between onset and symptom, lack of effective treatment, and low surveillance rate are key factors that restrain the malignant mesothelioma market.
In terms of geography, the malignant mesothelioma market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the malignant mesothelioma market, followed by Europe, due to the higher incidence and prevalence rate, rise in the geriatric population, and increase in demand for advance treatment. Asia Pacific is an emerging market for malignant mesothelioma due to the developing healthcare infrastructure, increase in patient awareness, and rising government expenditure in the healthcare industry. However, poor patient awareness, lack of proper treatment, and high cost of therapy are factors restraining the malignant mesothelioma market in Middle East & Africa.
Get accurate market forecast and analysis on the Malignant Mesothelioma Treatment Market. Request a sample to stay abreast on the key trends impacting this market.
Major players operating in the malignant mesothelioma market include Eli Lilly and Company, AstraZeneca plc, Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Epizyme, Inc, Bayer AG, Aduro Biotech, Ono Pharmaceutical Co., Ltd., Polaris Pharmaceuticals, Inc., Calithera Biosciences, Inc., and CBT Pharmaceuticals, Inc.
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact